Cost-effectiveness analysis of dolutegravir plus backbone compared with raltegravir plus backbone, darunavir+ritonavir plus backbone and efavirenz/tenofovir/emtricitabine in treatment naïve and experienced HIV-positive patients

• Principais autores: Restelli U (Autor), Rizzardini G (Autor), Antinori A (Autor), Lazzarin A (Autor), Bonfanti M (Autor), Bonfanti P (Autor), Croce D (Autor)
• Formato: Livro
• Publicado em: Dove Medical Press, 2017-06-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

Umberto Restelli,1,2 Giuliano Rizzardini,3,4 Andrea Antinori,5 Adriano Lazzarin,6 Marzia Bonfanti,1 Paolo Bonfanti,7 Davide Croce1,2 1Centre for Research on Health Economics, Social and Health Care Management, LIUC – Università Cattaneo, Castellanza, Varese, Italy; 2School of Pu...